Documentos relacionados

1. VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management.
2. MYELODYSPLASTIC SYNDROME: DIAGNOSIS, TREATMENT AND PROGNOSIS (LITERATURE REVIEW).
3. [Management of patients with higher-risk myelodysplastic syndromes].
4. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
5. Five-day versus 7-day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial.
6. VEXAS syndrome: complete molecular remission after hypomethylating therapy.
7. [Treatment for myelodysplastic syndromes and future perspectives in the genomic era].
8. Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry.
9. Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system.
10. Myelodysplastic syndromes: Contemporary review and how we treat.